Alnylam

Investor Relations



NASDAQ: ALNY (Common):

Price: $70.83
Change (%): -4.96 (-6.54%)
Volume: 808,598
Data as of 4:00 PM ET on 08.24.2016
Minimum 20 Minute Delay
Stock price graph
     

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company’s “Alnylam 5x15™” product strategy. Alnylam’s genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

Read more




View all releases  RSS

Recent Releases




View all events

Events